ABBV
Healthcare
AbbVie Q3 2026: Skyrizi And Rinvoq Are 49% Of Revenue, And Adjusted EPS Includes IPR&D
AbbVie's Skyrizi and Rinvoq are 48.7% of Q3 2026 revenue and about 98% of its growth, while adjusted EPS of $3.82 includes $0.69 of year-to-date acquired IPR&D charges.